# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0219 |
| Population Package | PP-0219 |
| Title | Post-treatment Imaging |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Decision Status | APPROVED / LOCKED |
| Source Strategy | Source-First |
| QA Standard | Four-layer Gold QA + safety + traceability + depth integrity |

---

# Layer 1 — Content QA

| Criterion | Result | QA Finding |
|---|---|---|
| Single educational question | PASS | Package answers one atomic question: how post-treatment imaging is used to reassess gastric cancer after treatment. |
| Scope respected | PASS | Content remains centered on post-treatment imaging, restaging and the imaging-to-assessment interface. |
| Complete coverage of objectives | PASS | All educational objectives are represented in CKO knowledge blocks and patient-facing sections. |
| Internal consistency | PASS | Timing, modality, response, surveillance and recurrence distinctions remain consistent. |
| Logical organization | PASS | CKO proceeds from purpose → timing → modality → comparison → findings → response interface → safety. |
| Knowledge blocks complete | PASS | Core concepts, patient explanation, clinical importance and key messages are represented. |
| Patient-facing explanation complete | PASS | Major patient questions and misconceptions are explicitly addressed. |
| Included/excluded scope explicit | PASS | Scope, exclusions and delegation are stated. |
| Atomic Knowledge Principle | PASS | PP does not become a general imaging, surveillance or treatment package. |
| No material duplication with PP-0068 | PASS | General follow-up imaging is treated as prerequisite/foundational context; PP-0219 owns post-treatment reassessment. |
| No material duplication with PP-0217 | PASS | Response assessment is referenced at interface level only. |
| No material duplication with PP-0218 | PASS | RECIST technical rules are delegated. |
| Surveillance boundary preserved | PASS | PP-0220 is explicitly downstream. |
| Recurrence boundary preserved | PASS | PP-0221 is explicitly downstream. |

---

# Layer 2 — Clinical QA

| Criterion | Result | QA Finding |
|---|---|---|
| Scientifically coherent | PASS | Clinical model is consistent with the supplied NCCN and ESMO-ASCO materials. |
| Consistent with NCCN v2.2026 | PASS | Post-treatment assessment, restaging, CT, PET/CT, selected EGD/biopsy and surveillance separation are preserved. |
| Consistent with ESMO-ASCO 2023 | PASS | Imaging modality, measurement error, RECIST interface and clinical judgment are appropriately represented. |
| Timing appropriately qualified | PASS | The 5–8 week example is explicitly presented as pathway-specific rather than universal. |
| CT role accurately framed | PASS | CT is described as a major modality in relevant pathways, not a universal requirement. |
| PET/CT accurately framed | PASS | PET/CT is described as clinically indicated/selected. |
| MRI accurately framed | PASS | MRI is presented as a selected alternative rather than a universal replacement for CT. |
| Contrast accurately framed | PASS | Contrast is described conceptually; detailed safety is delegated. |
| Baseline comparison accurately framed | PASS | Comparison with prior imaging is emphasized without claiming that all scans are technically interchangeable. |
| Treatment-related change recognized | PASS | Residual or new abnormalities are not automatically equated with cancer. |
| Negative imaging limitations preserved | PASS | “No detectable disease” is not translated into guaranteed cure. |
| New finding limitations preserved | PASS | New finding is not automatically equated with recurrence. |
| RECIST boundary correct | PASS | RECIST is treated as a standardized assessment framework, not the imaging study itself. |
| Individual clinical judgment preserved | PASS | No treatment decision is derived from imaging alone. |
| Immunotherapy context appropriate | PASS | iRECIST is acknowledged but not technically reproduced. |
| MSI-H/dMMR pathway appropriately qualified | PASS | NCCN-specific pathway is presented as a selected context. |
| No unsupported universal imaging schedule | PASS | No universal interval is invented. |
| No individualized diagnosis | PASS | Patient-specific interpretation is explicitly excluded. |
| No treatment prescription | PASS | No start/stop/change treatment instruction is provided. |

---

# Layer 3 — Educational QA

| Criterion | Result | QA Finding |
|---|---|---|
| Plain language | PASS | Medical terms are explained in patient-facing language. |
| Appropriate for patients | PASS | Content answers practical questions patients may ask after treatment. |
| Medical terminology explained | PASS | Restaging, post-treatment assessment, RECIST and indeterminate findings are explained. |
| Learning objectives satisfied | PASS | Objectives map to explicit knowledge blocks. |
| Common misconceptions addressed | PASS | Major misconceptions about cure, recurrence, scans and RECIST are addressed. |
| Clinical uncertainty preserved | PASS | Indeterminate and discordant findings are explicitly included. |
| Patient questions included | PASS | Structured questions help patients communicate with the care team. |
| Patient safety framing | PASS | Scan results are not converted into individualized treatment instructions. |
| No sensational language | PASS | Neutral wording is used throughout. |
| No false certainty | PASS | Context-dependent statements retain qualification. |
| Patient journey placement clear | PASS | Package is positioned after treatment and before surveillance/recurrence branches. |
| Educational atomicity preserved | PASS | Package does not become a general oncology imaging encyclopedia. |

---

# Layer 4 — Governance QA

| Criterion | Result | QA Finding |
|---|---|---|
| CKO completed | PASS | 01_CKO.md present and structurally complete. |
| Knowledge Passport completed | PASS | 02_KNOWLEDGE_PASSPORT.md present and complete. |
| Evidence Package completed | PASS | 03_PRIMARY_EVIDENCE_PACKAGE.md present and traceable. |
| QA Report completed | PASS | This artifact is substantive and includes all required layers. |
| Gold structure preserved | PASS | Four-artifact structure retained. |
| Semantic versioning | PASS | v1.0.0 applied consistently. |
| Knowledge Graph complete | PASS | Prerequisite, related, downstream and delegated relationships defined. |
| Boundary defined | PASS | One clean ownership boundary prepared for final production response. |
| Source-First rule | PASS | PP-specific clinical sources were searched first. |
| Locked Decision integrity | PASS | Production follows the approved PP-0219 Decision Batch. |
| User-controlled sequence | PASS | No next PP is selected or inferred. |
| ZIP package | PASS | Four artifacts packaged into one ZIP. |
| Filename compliance | PASS | Filename includes PP number, full title, GOLD and version. |
| Repository-ready structure | PASS | Package contains the four required markdown artifacts. |

---

# Clinical Safety Review

## Safety Principle

The PP must never allow a patient to infer that an imaging result alone determines:

- cure;
- recurrence;
- treatment success;
- treatment failure;
- treatment continuation;
- treatment discontinuation;
- surgical eligibility.

### QA

| Safety Item | Result |
|---|---|
| No individualized diagnosis | PASS |
| No individualized treatment recommendation | PASS |
| No universal imaging schedule | PASS |
| No unsupported claim that negative imaging proves cure | PASS |
| No unsupported claim that new finding proves recurrence | PASS |
| No claim that RECIST automatically decides treatment | PASS |
| No unsupported claim that PET/CT is universally superior | PASS |
| No unsupported claim that MRI universally replaces CT | PASS |
| No unqualified immunotherapy response algorithm | PASS |
| Appropriate referral to oncology/radiology/MDT context | PASS |

---

# Patient Misconception Review

| Misconception | Result | Action |
|---|---|---|
| “No visible disease means cure.” | PASS | Corrected explicitly. |
| “Any new spot is recurrence.” | PASS | Corrected explicitly. |
| “Any residual abnormality means treatment failure.” | PASS | Treatment-related changes discussed. |
| “More scans are always better.” | PASS | Clinical-question principle preserved. |
| “PET/CT is always better than CT.” | PASS | Modality selection qualified. |
| “RECIST is the scan.” | PASS | Imaging/RECIST distinction explained. |
| “RECIST determines treatment.” | PASS | Clinical judgment boundary explained. |
| “Post-treatment imaging is surveillance.” | PASS | PP-0219/PP-0220 boundary explained. |
| “A favorable immunotherapy scan automatically means no surgery.” | PASS | NCCN MSI-H/dMMR uncertainty preserved. |
| “An unclear scan means no answer is possible.” | PASS | Additional-assessment pathway explained. |

---

# Adjacent PP Overlap Audit

## PP-0068 — Follow-up Imaging

**Status: PASS**

PP-0068 owns foundational repeated/follow-up imaging and longitudinal comparison.

PP-0219 owns the **post-treatment reassessment event**.

No substantive duplication detected.

---

## PP-0217 — Response Assessment

**Status: PASS**

PP-0217 owns the broader clinical concept of treatment response.

PP-0219 owns the imaging evidence and reassessment event.

No substantive duplication detected.

---

## PP-0218 — RECIST-based Assessment

**Status: PASS**

PP-0218 owns formal RECIST assessment.

PP-0219 references RECIST only at the imaging-to-assessment interface.

No detailed RECIST criteria are duplicated.

---

## PP-0220 — Surveillance After Gastric Cancer Treatment

**Status: PASS**

Long-term surveillance is explicitly excluded from PP-0219.

The NCCN distinction between GAST-6 post-treatment assessment and GAST-7 follow-up/surveillance is preserved.

---

## PP-0221 — Recurrence Detection

**Status: PASS**

Recurrence detection is explicitly delegated.

PP-0219 may mention that recurrence can be detected on imaging but does not own the recurrence algorithm.

---

## Modality Packages

**Status: PASS**

CT, MRI, PET/CT and contrast methodology remain delegated.

---

# Evidence Traceability Audit

## Primary Claim Groups

### Claim Group A — Post-treatment assessment/restaging

**Source:** NCCN Gastric Cancer v2.2026, GAST-6 and relevant response-assessment pathways.

**Result:** TRACEABLE — PASS.

### Claim Group B — CT / PET/CT / MRI

**Source:** NCCN v2.2026.

**Result:** TRACEABLE — PASS.

### Claim Group C — Treatment-specific timing

**Source:** NCCN v2.2026, relevant 5–8 week pathway.

**Result:** TRACEABLE — PASS.

### Claim Group D — Baseline/follow-up imaging and measurement error

**Source:** ESMO-ASCO 2023 response-evaluation curriculum.

**Result:** TRACEABLE — PASS.

### Claim Group E — RECIST does not replace clinical judgment

**Source:** ESMO-ASCO 2023.

**Result:** TRACEABLE — PASS.

### Claim Group F — Immunotherapy/iRECIST context

**Source:** ESMO-ASCO 2023; NCCN v2.2026.

**Result:** TRACEABLE — PASS.

### Claim Group G — Surveillance separation

**Source:** NCCN GAST-6/GAST-7.

**Result:** TRACEABLE — PASS.

---

# Numerical Evidence Audit

## Audited Numerical Statements

### 5–8 weeks

**Result: PASS**

The interval is presented only as an example within the relevant NCCN preoperative/perioperative immunotherapy pathway.

It is explicitly not generalized into a universal schedule.

### Other numerical claims

No unsupported numerical threshold or universal imaging interval was introduced.

**Overall Numerical Evidence Audit: PASS**

---

# Knowledge Graph Audit

## Prerequisite

PASS:

- Follow-up Imaging;
- CT;
- MRI;
- PET/CT;
- Contrast;
- Response Assessment;
- RECIST.

## Related

PASS:

- perioperative/neoadjuvant treatment;
- immunotherapy;
- MSI-H/dMMR;
- toxicity/supportive care;
- multidisciplinary management.

## Downstream

PASS:

- surveillance;
- recurrence detection;
- recurrent disease management.

## Delegation

PASS:

Technical modality, RECIST/iRECIST, surveillance, recurrence, pathology and treatment decisions are delegated.

---

# Gold Depth Integrity Review

## Standard

CORE_WORKING_RULES WR-009 establishes:

> **Gold Reference Depth is a Minimum Standard.**

The approved Discussion Gold reference is the minimum depth for Decision Batches.

The Gold artifact specification requires the same minimum production depth for:

1. CKO;
2. Knowledge Passport;
3. Primary Evidence Package;
4. QA Report.

## Audit

### 01_CKO.md

**PASS**

Contains:

- metadata;
- objectives;
- detailed scope;
- extensive knowledge blocks;
- clinical importance;
- patient explanations;
- misconceptions;
- key messages;
- patient questions;
- safety;
- Knowledge Graph;
- Boundary;
- revision history.

### 02_KNOWLEDGE_PASSPORT.md

**PASS**

Contains:

- identity;
- classification;
- patient journey;
- runtime usage;
- retrieval metadata;
- clinical scope;
- knowledge units;
- evidence classification;
- sources;
- governance metadata;
- Knowledge Graph;
- Boundary Map;
- runtime safety;
- versioning;
- update triggers.

### 03_PRIMARY_EVIDENCE_PACKAGE.md

**PASS**

Contains:

- clinical question;
- educational intent;
- scope;
- source hierarchy;
- evidence matrix;
- detailed evidence notes;
- claims summary;
- consistency review;
- limitations;
- evidence gaps;
- maturity;
- patient translation;
- traceability;
- boundary verification;
- Knowledge Graph;
- update triggers.

### 04_QA_REPORT.md

**PASS**

Contains substantive:

- Content QA;
- Clinical QA;
- Educational QA;
- Governance QA;
- Clinical Safety Review;
- Patient Misconception Review;
- Adjacent PP Overlap Audit;
- Evidence Traceability Audit;
- Numerical Evidence Audit;
- Knowledge Graph Audit;
- Gold Depth Integrity Review;
- Source-First Audit;
- Locked Decision Integrity;
- Cross-artifact consistency;
- Package integrity.

### Overall Gold Depth Integrity

# **PASS**

No artifact was intentionally compacted into an executive-summary format.

---

# Source-First Audit

## Required rule

PP-specific clinical Source Materials must be searched before production.

## Audit result

**PASS**

The PP-0219 production was based first on the supplied project sources, particularly:

- NCCN Gastric Cancer v2.2026;
- ESMO-ASCO 2023;
- NCI treatment materials;
- ACS gastric-cancer materials;
- PP Registry;
- Gold Discussion reference;
- adjacent PP architecture.

No external web source was silently substituted for the project evidence base.

---

# Locked Decision Integrity

## Locked decision

The Project Coordinator explicitly approved and locked the full PP-0219 Decision Batch.

## Production test

The artifacts preserve the locked recommendation:

> PP-0219 is a specialized post-treatment imaging package centered on reassessment/restaging after a treatment milestone, with treatment-context-dependent timing, clinical-level modality selection, baseline comparison, interpretation of post-treatment findings, and interface with response assessment.

## Result

**PASS**

No material scope reopening occurred during artifact production.

---

# Cross-artifact Consistency

| Scope Element | CKO | KP | EP | QA | Result |
|---|---|---|---|---|---|
| Post-treatment imaging | ✓ | ✓ | ✓ | ✓ | PASS |
| Restaging | ✓ | ✓ | ✓ | ✓ | PASS |
| CT/PET/CT/MRI | ✓ | ✓ | ✓ | ✓ | PASS |
| Baseline comparison | ✓ | ✓ | ✓ | ✓ | PASS |
| Residual/new/indeterminate findings | ✓ | ✓ | ✓ | ✓ | PASS |
| RECIST interface | ✓ | ✓ | ✓ | ✓ | PASS |
| Surveillance exclusion | ✓ | ✓ | ✓ | ✓ | PASS |
| Recurrence exclusion | ✓ | ✓ | ✓ | ✓ | PASS |
| Treatment decision exclusion | ✓ | ✓ | ✓ | ✓ | PASS |
| Patient-facing safety | ✓ | ✓ | ✓ | ✓ | PASS |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ | PASS |
| Boundary | ✓ | ✓ | ✓ | ✓ | PASS |

---

# Package Integrity

## Required Files

- `01_CKO.md` — PRESENT
- `02_KNOWLEDGE_PASSPORT.md` — PRESENT
- `03_PRIMARY_EVIDENCE_PACKAGE.md` — PRESENT
- `04_QA_REPORT.md` — PRESENT

## ZIP

- Single ZIP package created.
- Filename contains PP number.
- Filename contains full package title.
- Filename contains GOLD.
- Filename contains version.
- ZIP contains exactly the four required Gold markdown artifacts.

**Package Integrity: PASS**

---

# Final Quality Decision

# PASS

PP-0219 satisfies the locked Gold Population Package production standard.

The evidence base is sufficient for the approved scope.

No critical evidence gap or architecture blocker was identified.

The package preserves:

- source-first evidence;
- atomic clinical ownership;
- adjacent PP boundaries;
- patient-facing safety;
- Knowledge Graph continuity;
- evidence traceability;
- Gold depth;
- four-artifact structure;
- semantic versioning.

---

# Reviewer Notes

PP-0219 should be treated as the dedicated **post-treatment imaging reassessment node** in the treatment-assessment branch.

Its clean architecture is:

**PP-0068 Follow-up Imaging**
→ foundational repeated imaging

**PP-0217 Response Assessment**
→ clinical meaning of response

**PP-0218 RECIST-based Assessment**
→ standardized RECIST interpretation

**PP-0219 Post-treatment Imaging**
→ treatment-context-specific imaging reassessment/restaging

**PP-0220 Surveillance**
→ long-term follow-up

**PP-0221 Recurrence Detection**
→ recognition/establishment of recurrence

This separation should be preserved in future updates.

---

# Final Status

**PASS — GOLD — READY FOR INTEGRATION**
